Endometrial Hyperplasia: A Review

Obstetrical and Gynecological Survey

Volumn 59, Issue 5, 2004, Pages 368-378

  Montgomtery, Ben E ^a,d   Daum, Gary S ^a   Dunton, Charles J ^b,c  

^a LANKENAU HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Albert Einstein Hospital   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GONADORELIN AGONIST; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRIPTORELIN;

BREAST CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CURETTAGE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; EPIDEMIOLOGICAL DATA; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTEROGRAPHY; HYSTEROSCOPY; PATHOGENESIS; PHARMACEUTICAL CARE; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY;

ALGORITHMS; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 1942509651     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200405000-00025     Document Type: Review

References (75)

1. The American Cancer Society. Cancer Facts and Figures 2003 [ACS web site]. Available at: http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf Accessed April 22, 2003.
2. Antunes CMF, Stolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979;300:9-13.
3. Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogen characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993;3:308-318.
4. Jick H, Watkins RN, Hunter J, et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979;300:218-222.
5. Shapiro S, Kaufan DW, Slone E, et al. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 1980;303:485-489.
6. Terakawa N, Kigawa J, Taketani Y, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 1997;23:223-230.
7. Ronnett BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 5th ed. New York: Springer-Verlag, 2002:467-500.
8. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer (Phila) 1985;56:403-412.
9. Tsujimoto Y, Finger LR, Yunis JM, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14:18) chromosome translocation. Science 1984;226:1097-1099.
10. Cleary ML, Sklar J. Nucleotide sequence of a t(14:18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985;82:7439-7443.
11. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14:18) translocation. Cell 1986;47:19-28.
12. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995;26:89-93.
13. McDonell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
14. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinoma. Cancer 1995;75:2209-2213.
15. Ritter JH, Dresler CM, Wick MR. Expression of bcl-2 protein in stage T1NOM0 non-small cell lung carcinoma. Hum Pathol 1995;26:1227-1232.
16. Swanson PE, Humphrey PA, Dehner LP. Immunoreactivity for bcl-2 protein in primitive neuroectodermal tumors. Appl Immunohistochem 1993;1:182-187.
17. Lu QL, Abel P, Foster CS, et al. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996;27:102-110.
18. Nunez G, London L, Hockenbery D, et al. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.
19. Gompel A, Sabourin JC, Martin A, et al. bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994;144:1195-1202.
20. Otsuki Y, Misaki O, Sugimoto O, et al. bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 1994;344:28-29.
21. Hopwood D, Levison DA. Atrophy and apoptosis in the cyclical human endometrium. J Pathol 1975;119:159-166.
22. Niemann TH, Trgovac TL, McGaughy VR, et al. bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1996;63:318-322.
23. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959;12:1106.
24. Casper RF. Regulation of estrogen/progesterone receptors in the endometrium. Int J Fertil 1996;41:16-21.
25. Amezcua CA, Zheng W, Muderspach LI, et al. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. Gynecol Oncol 1999;73:126-136.
26. Abulafia O, Triest WE, Adcock JT, et al. The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia. Gynecol Oncol 1999;72:193-198.
27. Wang S, Pudney J, Song J, et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia-precursor of endometrial cancer. Gynecol Oncol 2003;88:108-117.
28. Maruo T, Laoag-Fernandez JB, Pakarinen P, et al. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 2001; 16:2103-2108.
29. Lidor A, Ismajovich B, Condino E, et al. Histopathologic findings in 226 women with postmenopausal uterine bleeding. Acta Obstet Gynecol Scand 1986;65:41-43.
30. Hall TE, Stapleton JJ, McCance JM. The isolated finding of histiocytes in Papanicolaou smears from postmenopausal women. J Reprod Med 1982;27:647-650.
31. Chhieng DC, Elgert P, Cohen JM, et al. Clinical implications of atypical glandular cells of undetermined significance, favor endometrial origin. Cancer 2001;93:351-356.
32. Koonings PP, Price JH. Evaluation of atypical glandular cells of undetermined significance: is age important? Am J Obstet Gynecol 2001;184:1457-1461.
33. Wright TC, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-2129.
34. Gucer F, Reich O, Tamussino K, et al. Concomitant endometrial hyperplasia in patients with endometrial carcinoma. Gynecol Oncol 1998;69:64-68.
35. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982;49:2547-2559.
36. Tavassoli FA, Kraus FT. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol 1978; 70:770-779.
37. King A, Seraj IM, Wagner RJ. Stromal invasion in endometrial carcinoma. Am J Obstet Gynecol 1984;149:10-14.
38. Janicek MF, Rosenhein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol 1994;52:373-378.
39. Widra EA, Dunton CJ, McHugh M, et al. Endometrial hyperplasia and the risk of carcinoma. Int J Gynecol Cancer 1995; 5:233-235.
40. Kurman RJ, Felix JC, Archer DA, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000;96:373-379.
41. Portman DJ, Symons JP, Wilborn W, et al. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone. Am J Obstet Gynecol 2003;88:334-342.
42. Heuson JC. Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep 1976;60:1463-1466.
43. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-1321.
44. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
45. Achiron R, Lipitz S, Sivan E, et al. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound Obstet Gynecol 1995;6:116-120.
46. Cheng WF, Lin HH, Torng PL, et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and non-treated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66:233-237.
47. Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000;18:3459-3463.
48. Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050-2054.
49. Bertelli G. Venturini M. Del Mastro L. et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998;47:41-46.
50. Berliere M, Charles A, Galant C, et al. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-44.
51. Cecchini S, Ciatto S, Bonardi R, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996;60:409-411.
52. Seoud M, Shamseddine A, Khalil A, et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol 1999;75:15-19.
53. The American College of Obstetricians and Gynecologists. Committee Opinion: Tamoxifen and Endometrial Cancer. Compendium 2000. 2003;232:134-136.
54. Cummings S, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999;281:2189-2197.
55. Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000; 95:95-103.
56. Fugere P, Scheele WH, Shah A, et al. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-574.
57. Holst J, Koskela O, von Schoultz B, et al. Endometrial findings following curettage in 2018 women according to age and indications. Ann Chir Gynaecol 1983;72:274-277.
58. Kaminski PF, Stevens CW. The value of endometrial sampling in abnormal uterine bleeding. Am J Gynecol Health 1985;11: 33-36.
59. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-331.
60. Langer RD, Pierce JJ, O'Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997;337:1792-1798.
61. Gull B, Karlsson B, Milsom I, et al. Can ultrasound replace dilation and curettage? A longitudinal evaluation of post-menopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol 2003;188:401-408.
62. Stovall TG, Ling FW, Morgan PL. A prospective, randomized comparison of the Pipelle endometrial sampling device with the Novak curette. Am J Obstet Gynecol 1991;165:1287-1290.
63. Dijkhuizen FP, Mol BW, Brolmann HA, et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial cancer and hyperplasia: a meta-analysis. Cancer 2000;89:1765-1772.
64. Schwarzler P, Concin H, Bosch H, et al. An evaluation of sonohysterography and diagnostic hysteroscopy for the assessment of intrauterine pathology. Ultrasound Obstet Gynecol 1998;11:337-342.
65. Dueholm M, Lundorf E, Hansen ES, et al. Magnetic resonance imaging, transvaginal sonography, hysterosonographic examination and diagnostic hysteroscopy in evaluation of the uterine cavity. Fertil Steril 2001;76:350-357.
66. Ben YO, Kim YB, Leuchter RS. Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1998;68:4-7.
67. Ceci O, Bettocchi S, Pellegrino A, et al. Comparison of hysteroscopic and hysterectomy findings for assessing the diagnostic accuracy of office hysteroscopy. Fertil Steril 2002;78:628-631.
68. O'Connell LP, Fries MH, Zeringue E, et al. Triage of abnormal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. Am J Obstet Gynecol 1998;178:956-961.
69. Mihm LM, Quick VA, Brumfield JA, et al. The accuracy of endometrial biopsy and saline sonohysterography in the determination of the cause of abnormal uterine bleeding. Am J Obstet Gynecol 2002;186:858-860.
70. Gal D, Edman CD, Vellios F, et al. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983;146:316-321.
71. Guven M, Dikmen Y, Terek MC, et al. Metabolic effects associated with high-dose continuous megestrol acetate administration in the treatment of endometrial pathology. Arch Gynecol Obstet 2001;265:183-186.
72. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-440.
73. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-131.
74. Aorastos T, Bontis J, Bakiani A, et al. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathologic, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997;65:102-114.
75. Perez-Medina T, Bajo J, Folgueira G, et al. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol 1999;73:299-304.